MGTX News and Press, MeiraGTx Holdings plc From 05/20/22

The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event. For further details see: MeiraGTx (MGTX) Investor Presentation - Slideshow

MeiraGTx press release (NASDAQ:MGTX): Q1 GAAP EPS of -$0.70 misses by $0.19. Revenue of $5.63M (+22.4% Y/Y) beats by $1M. For further details see: MeiraGTx GAAP EPS of -$0.70 misses by $0.19, revenue of $5.63M beats by $1M

- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients - Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induced Xerostomia Completed Dosing of Both Unilateral and Bilateral Cohor...

LONDON and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage gene therapy company, today announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment...

The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event. For further details see: Corporate Presentation March 2022

LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as Presiden...

LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the follow...

MeiraGTx press release (NASDAQ:MGTX): FY GAAP EPS of -$1.80 beats by $0.29. Revenue of $37.7M (+142.3% Y/Y) beats by $19.48M. For further details see: MeiraGTx GAAP EPS of -$1.80 beats by $0.29, revenue of $37.7M beats by $19.48M

- Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enrolling and Dosing Patients - Received $30 Million Cash Milestone Payment from Janssen Pharmaceuticals, Inc. - Positive Preliminary Clinical...

-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the Phase 3 Lumeos Clinical Trial in X-linked Retinitis Pigmentosa -MeiraGTx Remains Eligible for Further Development and C...